CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study Prognostic Implication of Thermodilution Coronary Flow Reserve in Patients Undergoing Fractional Flow Reserve Measurement Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention) Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention Screening for Atrial Fibrillation With ECG: USPSTF Recommendation
|<<... 15 16 17 18 19 20 21 ...>>|

JOURNAL： Article Link

南京市第一医院心血管内科为一名难治性高血压患者成功实施肾动脉去交感神经消融术（RDN）

qiaomingyue Keywords: 高血压病被称为“无声的杀手”，全球高血压患者超13亿，而我国患者人数已突破3.4亿，且患病率仍在攀升。在我国3.4亿高血压患者中，近20%为难治性人群。针对高血压防控的难点，南京市第一医院心内科于河西院区成立“高血压中心”，致力于推动高血压诊疗新技术的研发及临床应用。

网站资料更新中...
>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top